In cases of CDD with early-onset epilepsy, luteolin slows disease progression by suppressing microglial responses, reducing NMDA receptor-induced cell death, and increasing brain-derived neurotrophic factor (BDNF) levels. This evidence concerns the gene BDNF and craniodiaphyseal dysplasia.